Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

03. September 2024 08:15 ET | Quelle: Senti Biosciences, Inc.

Senti Bio to Participate in Upcoming Investor Conferences

Senti Bio will participate in two upcoming investor conferences in September.
13. August 2024 16:05 ET | Quelle: Senti Biosciences, Inc.

Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights

– Dose finding ongoing in Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML – – Commencement of $8 million grant award from CIRM...
05. August 2024 08:05 ET | Quelle: Senti Biosciences, Inc.

Senti Bio Announces Execution of Grant Award from California Institute for Regenerative Medicines (CIRM) for Clinical Development of SENTI-202

Senti Bio announced the commencement of a grant award of $8 million from the California Institute for Regenerative Medicines (CIRM).
21. März 2024 16:05 ET | Quelle: Senti Biosciences, Inc.

Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights

– IND for SENTI-202, a potential first-in-class logic-gated treatment for AML, cleared by the U.S. FDA; First patient dosing anticipated in the second quarter of 2024 – – Cash and anticipated...
26. Mai 2023 12:26 ET | Quelle: Johnson Fistel, LLP

(SPAC) Special Purpose Acquisition Investigation: BBAI, TNGX, SNTI, GMTX, Contact Shareholder Rights Law Firm Johnson Fistel

SAN DIEGO, May 26, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of law in connection with the following special purpose acquisition...